CSIMarket


Bio path Holdings Inc  (BPTH)
Other Ticker:  
 


 

Bio path Holdings Inc

BPTH's Financial Statements and Analysis



Bio path Holdings Inc narrowed first quarter of 2024 net loss per share of $-4.88 compare to net loss per share of $-13.20 recorded in the same quarter a year ago a decrease compare to $-4.45 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -4.88 $  0 Mill
$+8.32     Unch.    



Bio Path Holdings Inc's Revenue fell by 0 % in first quarter of 2024 (Mar 31 2024) year on year, to $0 million and declined by sequentially.


Bio Path Holdings Inc is

More on BPTH's Income Statement



Bio Path Holdings Inc in the first quarter of 2024 recorded net loss of $-3.157 million, an improvement compare to net loss of $-5.273 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-3.372 million realized in previous quarter.

More on BPTH's Growth

Bio Path Holdings Inc Inventories
In Mar 31 2024 company's net cash and cash equivalents decreased by $-1 million


Bio path Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Bio path Holdings Inc payed $ -13.79 cash per share, on a free-cash flow basis .




Company issued 0.17 million shares or 35.33 % in Mar 31 2024.


More on BPTH's Dividends

 Market Capitalization (Millions) 1
 Shares Outstanding (Millions) 1
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Bio path Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Bio path Holdings Inc had negative $ -13.79 cash flow per share, on a free-cash flow basis .




Company issued 0.17 million shares or 35.33 % in Mar 31 2024.


More on BPTH's Balance Sheets

 Market Capitalization (Millions) 1
 Shares Outstanding (Millions) 1
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Bio path Holdings Inc Earnings

Top Pharmaceutical Company Faces Operating Shortfall in First Quarter of 2024

Bio-Path Holdings, Inc., a Houston-based biotechnology company, recently announced the successfu...

Bio-Path Holdings Inc Sees Improved Operating Shortfall in Fourth Quarter Results

The recent fin...

Bio Path Holdings Inc Demonstrates Signs of Resilience with Improved Operating Shortfall in Fiscal Third Quarter of 2023

Interpreting the Financial Results of Bio Path Holdings Inc: A Struggle to Attain the Next Stage
As the reporting season for July to September 2023 progresses, several companies in the Major Pharmaceutical Preparations sector have announced their financial results. Among them, Bio Path Holdings Inc stands out with its operating shortfall of $-3.276 million for the third quarter of 2023. This figure is a slight improvement from the operating shortfall of $-3.546 million in the same quarter of the previous year, indicating signs of resilience for the company.
Bio Path Holdings Inc is one of the evolving companies in the pharmaceutical industry, continuously working to enhance its business model. In an ...

Business Expenses Surge at Bio Path Holdings Inc During April-June 2023, While Prospect for Revenue Growth Remains Uncertain

Bio Path Holdings Inc, a major player in the Major Pharmaceutical Preparations sector, has recently reported its earnings for the second quarter of 2023. Despite being overshadowed by leaders in the industry, the company's shareholders are hopeful for new revenue sources to emerge in the near future. However, the markets have shown less interest in the company's productivity improvement thus far.
In the April to June 30, 2023 interval, Bio Path Holdings Inc incurred an operating loss of $-4.242 million, a significant increase from the $-3.008 million loss in the corresponding quarter of the previous year. This widening net loss of $-4.234 million, combined with the absence of top-line growth, highlights ...

Major Pharmaceutical Preparations Company Faces Operating Shortfall in First Quarter of 2023

Bio Path Holdings Inc is a biosciences company that specializes in the development of targeted therapies for cancerous tumors. As the healthcare sector continues to grow and evolve, Bio Path Holdings Inc has become a major player in the field, with investors looking to the company for its latest earnings, developments, and revenue sources.
In January to March 31, 2023, Bio Path Holdings Inc's quarterly earnings report showed no modifications in revenue, disappointing investors who expected higher returns. Instead, they observed an operating shortfall of $-5.292 million. This shortfall increased in the most recent approaching cycle, as shareholders await new revenue sources that can help the company evolv...


Date modified: 2024-05-15T13:03:04+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com